Mainz Biomed B.V. (MYNZ)

USD 3.78

(-14.48%)

Market Cap (In USD)

7.56 Million

Revenue (In USD)

895.47 Thousand

Net Income (In USD)

-26.29 Million

Avg. Volume

1.73 Million

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.18-7.95
PE
-
EPS
-
Beta Value
0.076
ISIN
NL0015000LC2
CUSIP
N5436L101
CIK
1874252
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Medical - Diagnostics & Research
CEO
Mr. Guido Baechler
Employee Count
-
Website
https://mainzbiomed.com
Ipo Date
2021-11-05
Details
Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments on a molecular genetic basis; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany.

More Stocks